Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Sponsor: GlaxoSmithKline
Listed as NCT00305942, this PHASE2 trial focuses on Carcinoma, Small Cell and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- SCRI Development Innovations, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alexandria, United States , Anniston, United States , Bowling Green, United States , Chattanooga, United States , Cincinnati, United States , Collierville, United States , Fort Myers, United States , Gainesville, United States , Grand Rapids, United States , Jonesboro, United States and 6 more locations